TICKERNERD
Menu
MNPRMNPRHealthcare · Biotechnology

MNPR Stock Forecast: Monopar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$111
+3.38% on the day

The 13 Wall Street analysts covering Monopar Therapeutics, Inc. hold a median 12-month price target of $128 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$723.0M
Ticker Nerd rank
56 / 100
Median analyst target
$128
Analysts covering
13
Total return, dividends reinvested
1W
−4.4%
1M
+1.4%
YTD
+70.5%
1Y
+247.3%
From 52W high
−10.1%
From 52W low
+266.1%
$30
$124
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Monopar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
84
Quality
78
Value
77
Growth
53
Size
49
Revisions
39
Volatility
37
Issuance
36
Accruals
32

Momentum (84): The shares have been drifting up relative to others.

Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MNPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26MNPRHigh $145Median $128Low $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $100Median $128High $145

The green dot is the last close — the median target sits +14.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026BarclaysMaintainsOverweight$125 → $128
13 Aug 2026Cantor FitzgeraldDowngradeNeutral$109 → $119
12 Aug 2026BTIGMaintainsBuy$117 → $133
22 July 2026HC Wainwright & Co.MaintainsBuy—
22 July 2026HC Wainwright & Co.MaintainsBuy$105 → $125
30 June 2026BTIGMaintainsBuy—
30 June 2026BTIGMaintainsBuy$104 → $117
29 June 2026HC Wainwright & Co.ReiteratesBuy—
29 June 2026HC Wainwright & Co.ReiteratesBuy$105
30 Mar 2026Chardan CapitalMaintainsBuy—
23 Feb 2026BTIGReiteratesBuy—
2 Feb 2026BTIGReiteratesBuy—
29 Jan 2026Chardan CapitalMaintainsBuy—
14 Jan 2026BTIGReiteratesBuy—
9 Jan 2026Morgan StanleyInitiatesOverweight—
14 Nov 2025Raymond JamesDowngradeOutperform—
13 Nov 2025Chardan CapitalMaintainsBuy—
10 Nov 2025Leerink PartnersInitiatesOutperform—
9 Nov 2025Chardan CapitalMaintainsBuy—
13 Oct 2025BarclaysInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MNPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
1
Fundamentals

Monopar Therapeutics, Inc. (MNPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−58.4×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
5.5×

Cheaper than 20% of US stocks

EV / EBITDA
−35.3×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−19.5%

Higher than 31% of US stocks

Return on assets
−14.6%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MNPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNPRMonopar Therapeutics, Inc.$723.0M
56
BBOTBridgebio Oncology Therapeutics, Inc.$719.1M
12
CTMXCytomX Therapeutics, Inc.$709.1M
50
TECXTectonic Therapeutic, Inc.$704.3M
53
RGNXREGENXBIO, Inc.$700.1M
54
NVCTNuvectis Pharma, Inc.$742.7M
71
ZVRAZevra Therapeutics, Inc.$696.9M
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Monopar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNPR news & analysis

Monopar Appoints Jeffrey D. Kent, M.D.

GlobeNewsWire · 19 Aug 2026positive

Monopar Therapeutics announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, effective September 1, 2026. The company also reported that two abstracts on ALXN1840 (tiomolibdate choline), its late-stage Wilson disease candidate, were accepted for presentation at AASLD – The Liver Meeting 2026 in Denver.

Why it matters — MNPR watchers would note the new medical affairs leadership and the acceptance of abstracts on its late-stage Wilson disease candidate at a major hepatology conference, which highlight progress on the company's key development program.

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

Seeking Alpha · 18 Aug 2026positive

Monopar Therapeutics holds exclusive license rights to ALXN1840 for Wilson disease and continues radiotherapeutic development. The company is completing a rolling NDA submission for ALXN1840, which demonstrated statistically significant efficacy in phase 3 trials, presenting a potential catalyst for FDA approval and Priority Review Voucher upside.

Why it matters — A MNPR watcher would care because completion of the ALXN1840 rolling NDA submission and potential FDA approval represent a major upcoming milestone for the company's lead program.

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 12 Aug 2026neutral

Monopar Therapeutics announced its second quarter 2026 financial results and provided business updates on August 12, 2026. The company is a clinical-stage biopharmaceutical firm focused on treatments for patients with unmet medical needs.

Why it matters — MNPR watchers would care because the announcement provides a regular update on the company's financial status and its ongoing business progress.

FAQ

Frequently asked questions about MNPR stock

What is the MNPR stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Monopar Therapeutics, Inc. have a median 12-month price target of $128, with estimates ranging from $100 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNPR stock a buy right now?

Of the 13 analysts covering Monopar Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monopar Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNPR?

As at 22 Aug 2026, Monopar Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).

Will MNPR stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks Monopar Therapeutics, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNPR stock forecast for 2030?

No analyst covering Monopar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $145 over the next 12 months.

How has MNPR stock performed over the past year?

Monopar Therapeutics, Inc. returned +247.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Monopar Therapeutics, Inc. do?

Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for oncology and a therapy for Wilson disease.

What is the latest news on MNPR?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "Monopar Appoints Jeffrey D. Kent, M.D.". Monopar Therapeutics announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President and Head of Medical Affairs, effective September 1, 2026. The company also reported that two abstracts on ALXN1840 (tiomolibdate choline), its late-stage Wilson disease candidate, were accepted for presentation at AASLD – The Liver Meeting 2026 in Denver.

Company

About Monopar Therapeutics, Inc.

Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for oncology and a therapy for Wilson disease. Its current portfolio centers on advanced cancer programs built around the MNPR-101 platform, including imaging and therapeutic candidates designed to target solid tumors that express uPAR. The company is also advancing ALXN1840, a late-stage investigational medicine for Wilson disease, a rare genetic disorder that affects copper metabolism. Monopar Therapeutics Inc. develops its pipeline through internal research and licensing of late preclinical and clinical-stage assets, concentrating on areas with significant unmet medical need. Based in Wilmette, Illinois, the company operates as a specialized drug development business within biotechnology, with a focus on precision oncology and rare disease treatment.

CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. · 22 employees · United States · https://www.monopartx.com